Beth Israel Deaconess Medical Center 330 Brookline Ave; MB-428
Boston, MA 02215
Advanced Degree And Training Info:
Year
Institution
Area or Rank
1992
Cornell University Medical College
Medicine
1992
Tufts University
Heme/Onc Fellow
Research Team Listing
No team members listed
Areas of Interest:
Cancer & Hematologic
Major Research Theme:
I am a clinical investigator in oncology at Beth Israel Deaconess Medical Center (BIDMC) with a particular interest in therapies that enhance the immune response to cancer. The majority of patients under my care enter research trials that are translational in nature, with both laboratory and clinical endpoints. My work has been supported by industry and NIH grants. I serve as clinical director of the Biologic Therapy Program which is a major participant in two Specialized Projects of Research Excellence (SPORE) grants from the National Cancer Institute in skin and kidney cancer in the Dana Farber/Harvard Cancer Center.
McDermott DF, Regan MM, Clark JI, Flaherty LF, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter C, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. A randomized phase III trial of high-dose interleukin-2 verus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; Jan 1;23(1):133-141.
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin-2 Therapy for Renal Cancer, Clin Cancer Res 2005; May 15;11(10):3714-3721.
McDermott DF, Mier JW, Lawrence DP, van den Brink M, Clancy M, Rubin K, Atkins MB. A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine (CVD), Interleukin-2 (IL-2) and Interferon Alpha-2B (IFN) in Patients with Metastatic Melanoma. Clin Can Res 2000; 6:2201-2208.
McDermott DF, Trehu EG, Mier JW, Clancy M, Klempner M, Atkins MB. A Two-part Phase I Trial of High-Dose Interleukin-2 in Combination with Soluble (CHO) IL-1 Receptor (IL-1R). Clin Can Res 1998; 5:1203-1213.
Major Collaborative Activities:
Renal Cancer Program � Clinical Research Sub-Committee � Chair, Dana-Farber Harvard Cancer Center
Scientific Advisory Committee, Member, Clinical Research Center, Beth Israel Deaconess Medical Center
